Development Of An Ovarian Cancer Early-Detection Test
19/11/2020 14:26
Nov 19 (Reuters) - Aspira Women's Health Inc AWH.O :
* ASPIRA WOMEN'S HEALTH, INC. ANNOUNCES A COLLABORATIVE
AGREEMENT
WITH BAYLOR GENETICS FOR CO-DEVELOPMENT OF AN OVARIAN CANCER
EARLY-DETECTION TEST
Source text for Eikon: ID:nGNX5BBZdG
Further company coverage: AWH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aspira Women's Health
See all newsBrief: Aspira Women’S Health Announces Receipt Of Delisting Notification From Nasdaq
Brief: Aspira Women's Health On April 4, Enters Equity Purchase Agreement With Triton Funds
Brief: Aspira Women's Health Files For Offering Up To 50 Units, 50 Mln Pre-Funded Units
Brief: Aspira Women's Health Interim CFO John Kallassy Resigns
Brief: Aspira Women's Health Fails To Regain Nasdaq Compliance